ABEO logo

Abeona Therapeutics Inc.

ABEO
Healthcare|Biotechnology|US
$4.17
+0.26 (+6.65%)
DCF Value
$1.00
Tangible Book / Share
$2.24
Cash / Share
$2.57
Next Earnings Report
Nov 11, 2026
EPS est. -$0.14 · Revenue est. $14.8M
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Jul 10, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (2)

Mar 2029
Est. completion
P2P3MPS IIIA
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
NCT02716246n=36
Apr 2045
Est. completion
Recessive Dystrophic Epidermolysis Bullosa
A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
NCT07700966n=250

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2025
P3
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
NCT05725018

Recent Press Releases

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Oct 6, 2026 · GlobeNewsWire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Oct 1, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Sep 29, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Sep 24, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Sep 22, 2026 · GlobeNewsWire
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
Sep 18, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Sep 17, 2026 · PRNewsWire
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
Sep 16, 2026 · GlobeNewsWire

SEC Filings (62)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 23, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Sep 15, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Jul 10, 2026424B3Offering prospectusDocumentIndex
Jun 26, 2026S-8Employee stock planDocumentIndex
Jun 12, 20268-KMaterial eventDocumentIndex
Jun 12, 20268-KMaterial eventDocumentIndex
Jun 10, 20268-KMaterial eventDocumentIndex
Jun 4, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
May 4, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 27, 2026ARSAnnual report to holdersDocumentIndex
Apr 27, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 7, 20268-KMaterial eventDocumentIndex
Apr 6, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 20, 20268-KMaterial eventDocumentIndex
Mar 17, 202610-KAnnual reportDocumentIndex
Mar 17, 20268-KMaterial eventDocumentIndex
Mar 9, 20268-KMaterial eventDocumentIndex
Feb 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 12, 20258-KMaterial eventDocumentIndex
Oct 30, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 6, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 6, 2025SC 13GPassive 5%+ stakeDocumentIndex
Sep 30, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 202510-QQuarterly reportDocumentIndex
Aug 14, 20258-KMaterial eventDocumentIndex
Aug 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jul 18, 20258-KMaterial eventDocumentIndex